<DOC>
	<DOCNO>NCT00286117</DOCNO>
	<brief_summary>The purpose study assess difference disease-free survival post-menopausal woman hormone receptor-positive early breast cancer switch tamoxifen anastrozole continue tamoxifen .</brief_summary>
	<brief_title>ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ Women With Breast Cancer Treated With NOLVADEX Least 2 Years</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Postmenopausal status ; age ≤75 year ; histologically confirm invasive breast cancer metastases axillary lymph node ; oestrogen receptor status positive unknown ; primary treatment ( surgery +/ radiotherapy , +/ chemotherapy ) complete Clinical evidence metastatic disease ( include local remote recurrence , even patient appear complete remission time randomisation ) .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>